Zhejiang Garden Biopharmaceutical Co (300401) Fair Value & Analysis

Healthcare · CN · Market cap 8.5B CNY

A solid business, but screening 24% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥13.76). The favourable scenario is already priced in.
• Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (¥5.57 to ¥13.76) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

60‑month range ¥7.81 – ¥22.51 · fair‑value band ¥5.57 – ¥13.76 · the ¥14.12 price screens above the ¥10.77 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhejiang Garden Biopharmaceutical Co (300401) currently trades at ¥14.12, while our model-based Fair Value estimate is ¥10.77, implying the stock looks roughly 23.7% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Zhejiang Garden Biopharmaceutical Co generated revenue of 1.2B CNY at a net margin of 21.8%. Revenue declined 15.2% year over year. It earns a return on equity of 7.5%. Net debt stands at 657M CNY. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥5.57 (bear case) to ¥13.76 (bull case); at ¥14.12, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 32% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -24%, 300401 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (¥11.86) versus Growth DCF (¥4.20). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China.

Full company description

Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The company offers lanolin cholesterol series products, such as cholesterol and feed grade cholesterol; vitamin D3 products, including food additives compound nutrient fortifier SDS, food additives compound nutritional fortifier CO and MO, cholecalciferol, vitamin D3 particles, feed additive vitamin D3 oil, and VD3 resin oil; and 25 HydroxyVitamin D3 Progen, 25 hydroxyvitamin D3, and 25 hydroxyvitamin D3 powder. It also provides refined lanolin comprising anhydrous lanolin, wool oil, wool wax, low chroma ultra pure fat, lanolin alcohol, isopropyl lanolate, lanolinic acid, high acid fat, and wool acid biofuel/wool alcohol biofuel; and vitamin D3 environmental rodenticide. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zhejiang Garden Biopharmaceutical Co reported revenue of ¥1.2B in FY2025 versus ¥1.1B in FY2021, a compound +2.6%/yr. Reported net income was ¥305M in FY2025, compounding −10.9%/yr from FY2021.

300401 screens 24% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.